If both trials are positive, which strategy should come first? Drs. Vidal and Hamilton debate the sequencing of DESTINY-Breast11 and DESTINY-Breast05, balancing pCR goals against ILD rates and the ER-positive nuances that will reshape the HER2+ standard of care.
